Travere Therapeutics, Inc. TVTX
Set alert
49.26 USD -1.13 -2.24%
At close · Nov 2
47.47 -1.79 -3.63%
After hours · Nov 2, 4:00 PM ET
48.64 Day range 52.87
22.59 52-week range 68.73
- YTD
- +28.92%
- 1 year
- +40.10%
- Open
- 50.47
- Prev close
- 50.39
- Mkt cap
- 4.58B
- Vol
- 2.91M
- Avg vol
- 1.77M
- EPS
- -0.74
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 48.64
- High
- 52.87
- Forward P/E
- 9.14
- Beta
- 1.12
- Short ratio
- 5.59
- Inst. own
- 116.11%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 59.06
- 200-d avg
- 46.62
- 1y target
- 75.21
5Y chart
Events in this range
- Aug 6, 2025Earnings: -0.14; estimate -0.28; surprise 50%
- Oct 30, 2025Earnings: 0.28; estimate -0.31; surprise 190.32%
- Feb 19, 2026Earnings: 0.03; estimate 0.03; surprise 0%
- May 4, 2026Earnings: -0.39; estimate -0.3; surprise -30%
- Aug 4, 2026Earnings: -0.37; estimate -0.13465; surprise -174.79%
- Aug 6, 2026Rating: Wedbush · Outperform → Outperform
- Aug 6, 2026Rating: Canaccord Genuity · Buy → Buy
- Aug 10, 2026Rating: Evercore ISI Group · Outperform → Outperform
- Sep 22, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Sep 22, 2026Rating: Wedbush · Outperform → Outperform
- Sep 24, 2026Rating: Guggenheim · Buy → Buy
- Nov 2, 2026Earnings: —; estimate -0.09842; surprise —%
Signals (77)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 12, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 21, 2026 | 1 month ago |
| RSI: Overbought | Jun 8, 2026 | 4 months ago |
| RSI: Overbought | May 25, 2026 | 5 months ago |
| RSI: Overbought | Apr 27, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 13, 2026 | 6 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Mar 2, 2026 | 8 months ago |
| SMA: Bullish | Feb 16, 2026 | 8 months ago |
| SMA: Bearish | Feb 9, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 12, 2026 | 9 months ago |
| SMA: Bearish | Jan 5, 2026 | 10 months ago |
| RSI: Overbought | Oct 13, 2025 | 1 year ago |
| RSI: Overbought | Sep 22, 2025 | 1 year ago |
| SMA: Bullish | Sep 1, 2025 | 1 year ago |
| SMA: Bearish | Aug 25, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 11, 2025 | 1 year ago |
| SMA: Bullish | Jul 7, 2025 | 1 year ago |
| SMA: Bearish | May 12, 2025 | 1 year ago |
| SMA: Bearish | May 12, 2025 | 1 year ago |
| SMA: Bullish | Apr 28, 2025 | 1 year ago |
| SMA: Bullish | Apr 28, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| SMA: Bearish | Mar 3, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 3, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 3, 2025 | 1 year ago |
| RSI: Overbought | Feb 3, 2025 | 1 year ago |
| SMA: Bullish | Jan 13, 2025 | 1 year ago |
| SMA: Bearish | Jan 6, 2025 | 1 year ago |
| SMA: Bullish | Dec 30, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 16, 2024 | 1 year ago |
| SMA: Bearish | Dec 9, 2024 | 1 year ago |
| RSI: Overbought | Nov 25, 2024 | 1 year ago |
| RSI: Overbought | Sep 9, 2024 | 2 years ago |
| SMA: Bullish | Jun 24, 2024 | 2 years ago |
| SMA: Bullish | May 27, 2024 | 2 years ago |
| MACD: Buy Signal | May 13, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 22, 2024 | 2 years ago |
| SMA: Bearish | Mar 11, 2024 | 2 years ago |
| SMA: Bullish | Mar 4, 2024 | 2 years ago |
| SMA: Bearish | Jan 29, 2024 | 2 years ago |
| SMA: Bullish | Dec 4, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 4, 2023 | 2 years ago |
| RSI: Oversold | Oct 2, 2023 | 3 years ago |
| RSI: Oversold | Sep 18, 2023 | 3 years ago |
| SMA: Bearish | Jul 31, 2023 | 3 years ago |
| SMA: Bullish | Jul 24, 2023 | 3 years ago |
| SMA: Bearish | May 1, 2023 | 3 years ago |
| SMA: Bearish | May 1, 2023 | 3 years ago |
| MACD: Sell Signal | May 1, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| SMA: Bearish | Apr 3, 2023 | 3 years ago |
| SMA: Bearish | Apr 3, 2023 | 3 years ago |
| SMA: Bullish | Mar 27, 2023 | 3 years ago |
| SMA: Bullish | Mar 27, 2023 | 3 years ago |
| SMA: Bearish | Mar 20, 2023 | 3 years ago |
| SMA: Bullish | Mar 13, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| SMA: Bullish | Feb 27, 2023 | 3 years ago |
| SMA: Bullish | Feb 20, 2023 | 3 years ago |
| SMA: Bearish | Feb 6, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 16, 2023 | 3 years ago |
| SMA: Bullish | Dec 26, 2022 | 3 years ago |
| MACD: Sell Signal | Oct 10, 2022 | 4 years ago |
| SMA: Bearish | Sep 19, 2022 | 4 years ago |
| SMA: Bearish | Sep 19, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bearish | Jul 18, 2022 | 4 years ago |
| SMA: Bullish | Jun 13, 2022 | 4 years ago |
| SMA: Bearish | Apr 25, 2022 | 4 years ago |
| SMA: Bullish | Mar 28, 2022 | 4 years ago |
Key statistics
- Market cap
- 4.58B
- Enterprise value
- 4.88B
- Trailing P/E
- 0.00
- Forward P/E
- 9.14
- PEG ratio
- 0.00
- Price / sales
- 7.75
- Price / book
- 189.46
- EPS (TTM)
- -0.74
- Beta
- 1.12
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -7.35%
- Revenue (TTM)
- 591.33M
- Revenue growth
- 48.20%
- Free cash flow
- -18.25M
- Total cash
- 489.18M
- Total debt
- 616.91M
- Return on equity
- -236.36%
- Shares outstanding
- 92.99M
- Short % of float
- 15.08%
- 50-day average
- 59.06
- 200-day average
- 46.62
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 75.21 +52.7% upside
Now 49.26
- Target (low)
- 62.00
- Target (mean)
- 75.21
- Target (high)
- 90.00
Ratings (0m) 15 14 buy · 1 hold · 0 sell
- Strong buy2
- Buy12
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate 0.41736.
Financials — quick view
TVTX Revenue — quarterly 169.58M
TVTX Net income — quarterly -34.80M
TVTX EPS — quarterly -0.37
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | -0.09842 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | -0.13465 | -0.37 | -0.24 | -174.79% |
| May 4, 2026 | Mar 31, 2026 | -0.30 | -0.39 | -0.09 | -30.00% |
| Feb 19, 2026 | Dec 31, 2025 | 0.03 | 0.03 | 0.00 | 0.00% |
| Oct 30, 2025 | Sep 30, 2025 | -0.31 | 0.28 | +0.59 | +190.32% |
| Aug 6, 2025 | Jun 30, 2025 | -0.28 | -0.14 | +0.14 | +50.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 24, 2026 | Guggenheim | main | Buy | Buy |
| Sep 22, 2026 | Wedbush | reit | Outperform | Outperform |
| Sep 22, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 10, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Aug 6, 2026 | Canaccord Genuity | main | Buy | Buy |
| Aug 6, 2026 | Wedbush | main | Outperform | Outperform |
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- travere.com
News
- Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings
- What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call
- Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
- Travere Therapeutics Q3 2026 Earnings Call Transcript
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Travere Therapeutics Q3 Adj. EPS $(0.31) Misses $(0.06) Estimate, Sales $224.563M Beat $195.292M Estimate
- Travere Therapeutics Reports Third Quarter 2026 Financial Results
- Travere Therapeutics to Report Third Quarter 2026 Financial Results
- Reported Friday, Travere Says PROTECT Biomarker Data Add To Superior Proteinuria Reduction, Slower Kidney Function Decline Versus Irbesartan, Supporting FILSPARI As Non-Immunosuppressive, Kidney-Targeted, Foundational First-Line Treatment For IgA Nephropathy
- Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
Your note
Sign in to keep a note on TVTX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Jupiter Topco LLC | 12.01% | 11,324,191 | 557.83M | Jun 29, 2026 |
| Blackrock Inc. | 8.51% | 8,020,663 | 395.10M | Jun 29, 2026 |
| FMR, LLC | 7.53% | 7,096,614 | 349.58M | Jun 29, 2026 |
| Bank of America Corporation | 4.85% | 4,568,341 | 225.04M | Jun 29, 2026 |
| State Street Corporation | 4.52% | 4,256,224 | 209.66M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.36% | 4,108,694 | 202.39M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.13% | 2,947,890 | 145.21M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.45% | 2,310,625 | 113.82M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.37% | 2,231,509 | 109.92M | Sep 29, 2026 |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 1.66% | 1,569,286 | 77.30M | Aug 30, 2026 |
| Vanguard Explorer Fund | 1.52% | 1,431,331 | 70.51M | Jul 30, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 1.50% | 1,413,117 | 69.61M | Jun 29, 2026 |